Your browser version is outdated. We recommend that you update your browser to the latest version.

Cancer Immunotherapy

Cancer Immunotherapy relies on use of the patients own immune system to fight the cancer. It is now clear that one step in the process of cancer development involves loss of efficient immune control, leading to tumor immune escape mechanisms with subsequent uncontrolled tumor progression.

Immunotherapeutic strategies that are now clinically used includes:

  • Some of the most promising new therapeutic strategies belong to the class of "Immune Checkpoint Inhibitors"; targeting CTLA-4, PD-1 or PD-L1, all involved in the mechanism of T-cells and their ability to fight the tumor cells. 
  • Systemic administration of cytokines eg. Proleukin®, (IL-2) and Intron®A (Interferon), used today as adjuvant therapies combined with chemotherapy.
  • CAR-T-cell technologies.
  • Therapeutic antibodies e.g. Avastin®, Rituxan® Erbitux® and Herceptin®. These drugs are among the top 10 selling anti-cancer drugs today with annual sales approaching 5 billion US$.